Best-in-class vs first-in-class
Zanubrutinib Surpasses Ibrutinib: A Case Study in Best-in-Class Innovation
BeOne Medicines is reshaping hematology with zanubrutinib. Superior efficacy, cleaner safety, and strong market momentum put it ahead of ibrutinib — a textbook case of best-in-class drugs eclipsing first-in-class pioneers.